Pharmacogenomics is the study of the interaction between drugs and the genome, in an effort to use a rational approach to maximize individual patient benefits and minimize adverse events. This potential was recognized as early as 510 BC by Pythagoras of Samos, when he noticed a connection between fava bean ingestion and hemolytic anemia in certain people. It was not until 1961 that a deficiency in G6PD was found to be responsible for favism. Around the same time, it was recognized that abnormalities in butyrycholinesterase can result in serious adverse reactions after succinylcholine-aided anesthesia. It took another half century before we had the first FDA-approved pharmacogenetic test for cytochrome CYP2D6 and CYP2C19 alleles. The FDA requires many drugs to carry labels warning of specific gene interactions (www.fda.gov/Drugs/ScienceResearch/ucm572698.htm).

GENETIC INFLUENCE
Age-related macular degeneration (AMD) is one of the most genetically influenced multigenic diseases found in humans, with more than 30 genes known to affect its risk and progression. Variants of two particular genes, complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), have the strongest influence on AMD development and progression. These genes have been shown not only to affect progression to the diseased state but also to affect patients’ responses to therapy.

A meta-analysis by Chen and colleagues of 13 studies involving more than 2,700 patients concluded that CFH Y402H polymorphism may play a role in patients’ response to anti-VEGF treatment for wet AMD, especially for white individuals. Similar results were found in the most recent and comprehensive meta-analysis, including more than 2,960 patients. Those authors reported that “individuals carrying the rs1061170/Y402H TT genotype were more likely to achieve a better treatment outcome (OR = 1.932, 95% CI = 1.125–3.317, P = .017) than those carrying the CC genotype.”

Controversy over the links between supplementation, genomics, and treatment response may have been due to researchers asking the wrong question.

BY DEMETRIOS G. VAVVAS, MD, PhD

Pharmacogenomics and Age-Related Macular Degeneration

AT A GLANCE

▶ Pharmacogenomics is the study of the interaction between drugs and the genome.

▶ More than 30 genes affect the risk for and progression of AMD.

▶ Used in clinical practice and in the management of patients with wet AMD, genetic information can help us better understand and treat the disease.
Another meta-analysis examining the ARMS2 A69S rs10490924 risk allele in more than 2,380 patients found that patients homozygous for the low-risk allele (GG) had a higher chance of better response compared with patients with TG or TT alleles (OR 1.34; P = 0.039). However, the subgroup analysis suggested that this finding may be driven by the Asian population and may not hold true in whites.7

A more recent prospective study of 103 white patients over 4 years revealed in multivariate analysis that the ARMS2 A69S rs10490924 high-risk allele TT patients had more recurrences than the low-risk allele patients.8

There are smaller studies on single-nucleotide polymorphisms (SNPs) of VEGF-A and kinase insert domain receptor (main VEGF receptor) and response to VEGF therapy. A meta-analysis of about 440 patients revealed that only one VEGF-A SNP (rs833061) was significantly associated with treatment response,9 and a study of 377 patients investigating the major VEGF co-receptor neuropilin-1 (NRP1) suggested that patients with AA or GA NRP1 SNP rs2070296 genotype performed worse at 3 months when compared with individuals who possessed the GG genotype.10

Given the heterogeneity in study designs and resulting heterogeneous findings, it is no surprise that genetic information continues to be underused in clinical practice and overlooked in the management of patients with wet AMD. Unlike wet AMD, for which there are efficacious treatments,11-13 there is no therapy shown to be effective for nonneovascular, or dry, AMD. Only one study, the Age-Related Eye Disease Study (AREDS) Report No. 8, has shown that supplementation with high-dose vitamins and zinc in patients with advanced AMD (categories 3 and 4) can reduce progression to advanced AMD by about 25%.14 Detailed analysis reported in this study revealed that only progression to the wet form of the disease was statistically significantly affected (0.62, 95% CI = 0.43–0.90, P = .001), whereas atrophic changes showed opposing, non–statistically significant trends, for central (decreasing trend, P = .13) or noncentral (increasing trend, P not provided) geographic atrophy (GA).

PHARMACOGENOMICS AND TREATMENT RESPONSE

Several years after AREDS Report No. 8 was published, several authors attempted to investigate the pharmacogenomics of this supplementation, leading to controversy in the literature. Investigating a combined endpoint of progression to both neovascular and central GA stage in a post hoc fashion, Klein et al suggested that the benefit of the AREDS formulation (PreserVision; Bausch + Lomb) may be reduced in patients with high CFH risk allele.15 A subsequent post hoc study by Awh et al, considering a partial cohort of the AREDS study population, suggested that high CFH risk may actually be harmful, and that patients with the ARMS risk allele may benefit even more from use of the formulation than the average patient.16 However, as noted, that study did not include the full AREDS dataset and lacked a validation group, which is important in any retrospective analysis. Subsequently, investigators for AREDS Report No. 38 could not replicate the interactions between genetics.
and response to supplementation reported by Awh et al. It is interesting to note, however, that AREDS Report No. 38 analyzed so many genetic subgroups and treatment variations that it resulted in small sample sizes for each subgroup and diminished overall statistical power. Thus, for each individual subgroup, the study could not identify any group with statistically significant benefit.

To increase statistical power, Awh et al subsequently analyzed only four subgroups based on CFH/ARMS2 risk alleles and replicated their original conclusions, still without including a validation cohort. Assel et al then further examined this controversy and could not find an interaction between supplements and genetics and progression to advanced AMD. It should be noted, however, that none of these studies evaluated progression only to wet AMD.

Seddon et al studied 4,124 eyes of AREDS patients and concluded that “the effectiveness of antioxidant and zinc supplementation appears to differ by genotype.” These authors also identified that the genetics-treatment interaction exists only for progression to the wet form of advanced AMD, and that “no significant treatment effect was observed for GA.” This is similar to the findings of the original AREDS Report No. 8.

**GENETICS: AN IMPORTANT PIECE OF THE PUZZLE**

My colleagues and I investigated the interaction between genetics and supplements using wet AMD, the only statistically significantly proven event in the AREDS study, as endpoint progression. Our study included the largest cohort of AREDS patients to date, plus 103 patients from an additional cohort (N = 1,624). We used several accepted statistical approaches to demonstrate a strong, statistically significant dependence of treatment outcome on genetics. More important, we used a validation dataset of 299 patients that demonstrated even stronger interaction.

These data provide further support that response to the AREDS formulation treatment differs substantially among individuals, based on genetic risk. Unlike FDA-approved drugs that must have two phase 3 randomized trials to demonstrate efficacy and safety before being allowed to go to market, there has been no placebo-controlled replication study of the efficacy of the AREDS supplements. This is because the manufacturer markets the formulation as a supplement with the disclaimer that it is not intended to treat or prevent any disease, rather than as a drug with therapeutic impact; thus, it bypasses FDA jurisdiction. Furthermore, the lack of a controlled replication-validation trial has not prevented the widespread acceptance and recommendation of the AREDS formulation treatment for patients with intermediate AMD.

If we want to better understand and treat this disease, it would behoove us to take advantage of the genetic information that we are now able to obtain. Our investigations and those of others suggest that pharmacogenomics is here to stay.